Introduction
(1) In life science experiments, we often want to answer a more causal question: Is a given protein actually responsible for the phenotype you observe?
- This is exactly where small-molecule chemical probes come in. A chemical probe is not meant to “visualize” a protein; instead, it is used to directly perturb a protein’s function in cells, thereby connecting target perturbation to phenotypic change more reliably.
(2) But in practice, another situation is very common:
- For the same class of small molecules, some people call them “probes,” while others call them “tool compounds.” After completing the experiment, you may indeed see the phenotype change—yet it could be caused by non-specific activity, cytotoxicity, assay/readout interference, or off-target effects. The result is: the data look strong, but the conclusion becomes harder to interpret, and the causal chain becomes weaker rather than stronger.
(3) Therefore, this article is organized around one central objective:
How do you select and use small molecules so that your conclusions are closer to “target causality,” rather than a “mixture of compound-driven effects”? The article is developed in 5 steps:
- Concepts and criteria: What is the difference between a tool compound and a chemical probe? When should you not call a molecule a “probe”?
- Experimental advantages: How do chemical probes provide temporal control and dose control, and strengthen causal inference?
- Where probes come from: What can HTS, phenotypic screening, fragment-based approaches, and chem
- oproteomics each solve—and where are the most common pitfalls?
- A usable public resource: How to leverage publicly available intracellular interaction / ligandability resources to find “starting points” faster and reduce blind trial-and-error.
- A ready-to-use checklist: The “Good Probe Six-Pack + Three Key Reminders”—a final pre-experiment check.
- Note: In this article, chemical probe specifically refers to probes used to modulate target protein function to support causal attribution. We do not discuss probes in the broader sense of imaging/detection probes.
Step 1 | Concepts and Criteria: Tool Compound ≠ Chemical Probe
Type | Definition (What it is) | Purpose (Why you use it) | Strength of conclusion it can support |
Tool compound | A small molecule used to perturb a biological process/pathway to explore mechanisms or validate a direction | Quickly assess whether a mechanism/pathway might be relevant and whether further validation is worth investing in | Better suited for hypothesis generation / directional judgment; not ideal for direct target-level causal attribution |
Chemical probe | A small molecule with a relatively complete evidence chain that can attribute a phenotype to a specific target protein | Establish a causal “target → phenotype” relationship for mechanism studies and target validation | Can support target attribution / causal inference, but still must be stated within its applicability boundaries |
Note:
The quality expectations for “chemical probes” here follow common expert-reviewed resources (e.g., the Chemical Probes Portal and public recommendations from SGC). These are closer to experience-based baselines / selection guidelines meant to reduce misinterpretation, and are not hard universal thresholds applicable to all targets. Common focal points include: sufficient potency, explainable selectivity, cellular on-target evidence, and orthogonal probes / matched negative controls (see Step 1.2 and Step 5).
1.2 The Difference Is Not “Can You Use It,” but “Is the Evidence Chain Sufficient for Attribution?”
Key dimension | Tool compound | Chemical probe |
Potency (effectiveness on the intended target) | May have “activity on a target,” but the data may come from limited experiments, be non-comparable across systems, or only show “phenotypic impact” rather than strong target engagement | Requires clear, reproducible quantitative values (e.g., IC₅₀/Kd) with assay conditions, demonstrating it is genuinely strong on-target rather than “working by chance.” This determines whether you can run clean experiments at lower concentrations. |
Selectivity | Often lacks systematic information: may hit multiple proteins within the same family or have known frequent off-targets. Acceptable in exploratory stages, but uncertainty must be acknowledged. | Needs data showing minimal impact on “the most easily confounded proteins” (especially same-family members, common off-targets, key safety targets). Selectivity determines whether a phenotype can be primarily attributed to a single target. |
Cellular on-target evidence (does it truly hit the target in cells?) | May only show “compound → phenotype.” But the phenotype can arise from toxicity, stress responses, membrane effects, or off-target pathways—not necessarily the intended target. | Requires cellular evidence supporting true target engagement: e.g., target engagement (occupancy/binding) data, or mechanism-consistent hallmark readouts, and the ability to rule out “global cell state disruption.” This is the critical step from correlation toward causality. |
Control strategy (how false positives are excluded) | Often only vehicle control, or an “unrelated compound” control—hard to exclude scaffold-driven or physicochemical effects. | Usually expects at least one strong control: a matched negative control (structurally similar but inactive/weakened on-target) and/or an orthogonal probe (a different scaffold that hits the same target). Controls separate “target effects” from “compound side effects.” |
Dose and interpretation (how much you use, how you write conclusions) | Frequently needs higher concentrations but the risk is not clearly discussed; higher doses are more likely to hit additional targets, widening interpretation space. | Emphasizes interpreting results within a validated on-target concentration window: aim to generate convergent evidence at lower doses and bind conclusions to specific concentration ranges and conditions to reduce misattribution. |
Fit-for-purpose positioning (what problem it is suited to solve) | Suited for exploration/screening: deciding whether a pathway might be relevant and worth pursuing; claims should be more cautious. | Suited for target attribution / mechanism research: supports arguments like “this protein causes this phenotype.” Causal claims can be stronger, but boundary conditions still must be stated. |
1.3 If You See These Signals, Do Not Treat the Molecule as a “Probe” for Causal Claims
Signal (what you observe) | Most likely issue (what it implies) | First-line mitigation (what to do next) |
Phenotype appears only at clearly high concentrations | Non-specific hits increase, or the main effect may not be from the intended target | Lower dose with a gradient; add target engagement; switch to a stronger/cleaner molecule |
No selectivity data, or known broad-spectrum activity | Off-target effects are hard to exclude | Run family-panel screening / key off-target checks; at minimum add same-family comparisons |
Phenotype accompanies obvious cytotoxicity/stress | Phenotype may be driven by toxicity or stress pathways | Add toxicity and stress readouts; use lower dose/shorter exposure windows |
No negative control and no orthogonal probe | Scaffold/physicochemical effects cannot be excluded | Add a matched negative control or a second-scaffold (orthogonal) probe |
Attribution based on a single phenotype readout | Attribution chain is too short | Add mechanism-linked readouts and orthogonal validation |
Step 2 | Core Value: Time Control + Dose Control + A Causal Inference Pathway
2.1 Three classes of “controllable variables” chemical probes provide in experimental design
Capability (what you can control) | What you can do (operationally) | What it helps answer (typical scenarios) | Why it strengthens interpretability (logic) | Reminder |
Time control (fast onset / reversibility) | Add compound at a defined timepoint; reduce/remove effect via washout, withdrawal, or antagonists (reversibility depends on mechanism and how “withdrawal” is done) | Acute processes, rapid signaling, dynamic feedback; distinguishing “early events” from “secondary downstream events” | Constrains intervention to a defined window, helping separate direct effects from downstream effects (clearer temporal order) | Not all small molecules are reversible; cellular retention, irreversible inhibition, or long half-life can make “switching off” incomplete—use time gradients to validate |
Dose control (continuous gradient) | Run concentration gradients to obtain dose–response curves; compare thresholds, saturation, nonlinear ranges; distinguish partial vs full inhibition | “Graded intensity” questions: thresholds/saturation, sensitive readout screening, defining a usable concentration window; comparing phenotype sensitivity to the same pathway | Continuous dose information constrains interpretation better than binary “on/off”: orderly dose-dependent changes better support intervention-related causality | High doses more easily trigger off-targets and stress; “effective” ≠ “attributable”—interpret within an explainable window |
Causal inference pathway (shrinking off-target explanation space) | Use “multiple lines of evidence for the same conclusion”: the same conclusion holds across different perturbation modes, different scaffolds, and key controls | Mechanism validation, target attribution, reliably linking phenotype to the target protein | When multiple independent pieces of evidence converge on the same target, the space of off-target explanations shrinks substantially | This step relies on Step 1 probe standards and control design; without selectivity/cellular engagement, phenotype alone cannot complete attribution |
Step 3 | Where Probes Come From: HTS / Phenotypic Screening / FBLD / Chemoproteomics
3.1 Four routes: strengths, blind spots, and “what to add next”
Route | What it is good at | Common blind spots / risks | Typical “what to add next” |
HTS (High-Throughput Screening) | Rapidly finds initial hits from large libraries that affect a readout / bind / inhibit; fast and broad coverage | Hits often include interferers / frequent hitters: colloidal aggregators, reactive compounds, readout interference (fluorescence/luminescence/redox cycling, etc.); high cost to triage artifacts | Anti-interference & de-artifacting: aggregation/readout checks; SAR reproducibility; orthogonal assays; early selectivity and usable concentration-window assessment |
Phenotypic screening | Directly optimizes for functional outcomes; can uncover new mechanisms/pathways without target assumptions | Target deconvolution is difficult; phenotypes may come from multi-target/network effects; mechanistic dissection is slow and needs extra work to reach a “explainable, reproducible target conclusion” | Target identification & causal reinforcement: chemoproteomics/thermal proteome profiling, etc.; genetic cross-validation; improved orthogonal probes and control systems |
FBLD (Fragment-Based Lead Discovery) | Uses small fragments to explore binding sites: hits are often weak but ligand-efficient and highly “growable/mergeable” for fine optimization | Requires structural/biophysical/medchem iteration; weak hits make validation more demanding (assay choice, protein quality, false-positive control) | Structural/biophysical confirmation; multi-method triangulation; site-guided fragment growth with property control; gradually add cellular evidence and selectivity boundaries |
Chemoproteomics (incl. ABPP, etc.) | Identifies which proteins/sites a compound binds or competes with in near-physiological settings; supports target confirmation, off-target profiling, ligandable-site discovery | Complex interpretation; substantial background binding; high demands on competition experiments, controls, and statistical thresholds—otherwise background may be mistaken as specific | Competition and controls: same-site competition, matched negative controls, dose dependence, replication and statistical control; then close the loop with functional assays and mechanism-linked readouts |
Step 4 | A Public Resource to Find “Starting Molecules” Faster and Reduce Blind Trial-and-Error
4.1 What problem does it solve?
1. Many people get stuck at the very first step when working with probes/tool molecules:
- “For the protein I care about, is there any small molecule that can bind? What kind of scaffold should I start from?”
The traditional path often requires doing HTS or fragment screening yourself—costly, slow, and uncertain.
2. The “public resource” here refers to:
- The Ligand Discovery interactive resource built by Offensperger et al. (Science, 2024). It converts large-scale live-cell chemoproteomics “fragment–protein interaction maps” into searchable data and a web tool, and is paired with machine learning models to help you more quickly locate starting points / chemical scaffolds likely worth optimizing.
- Importantly, it is not a ready-to-use “chemical probe library.” Instead, it is a starting-point navigator: it tells you which fragments are more likely to form capture-able interactions with which proteins in live cells, thereby narrowing the search space for subsequent probe optimization and validation.
4.2 What does it solve, and how should you use it?
Problem you face when “finding a probe starting point” | What to do in the resource | What usable output you get | You still must return to probe standards (Step 1 & Step 5) |
You have a target protein/pathway of interest but don’t know what scaffold to start from | Use Interactions (main entry) to search by protein | Fragment interaction information linked to that protein (to shortlist starting scaffolds) | Still need: potency/selectivity/cellular target engagement + negative controls/orthogonal probes |
You have a set of proteins (same family/pathway) and want to see which fragments are more likely to hit the set overall | Use Explore protein sets and input the protein set | Coverage of fragment interactions for that set (more like “starting-point opportunity assessment”) | Still need: target-by-target reproducible validation; exclude background and bias |
You worry certain fragments are too promiscuous (sticky everywhere) and will create high background | Use Fragment predictor (behavioral bias prediction) | Predict whether a fragment is more likely broad-spectrum or biased toward certain interaction features | Still need: verify interpretability in your own system with controls and a dose window |
You want quick prioritization of candidate interactions, rather than blind screening from scratch | Use On-the-fly modeling for rapid predictive modeling | Interpretable predictive results for your fragment/protein set (for ranking) | Treat predictions as “navigation,” not conclusions; final answers require experimental and control-based closure |
Reminder: Such public interaction maps solve the “starting-point selection” problem by shrinking the chemical space you would otherwise explore blindly. They do not replace chemical probe standards. To support causal attribution, you still need cellular on-target evidence and matched negative controls / orthogonal probes to close the loop.
Step 5 | A Ready-to-Use Checklist: The “Good Probe Six-Pack” + Three Key Reminders
5.1 The Good Probe Six-Pack
Six-Pack item | What you need to see (minimum information to report) | Why it matters (what conclusion it directly affects) | What to do if missing (most common fix) |
1. Potency: strong enough on the intended target | On-target activity/binding data (IC₅₀, Kᵢ, K_d, etc.) + reproducible concentration–effect relationship; ideally with assay system and conditions | If not strong enough, you’ll be forced into high doses, raising off-target risk—controls may not rescue interpretability | Find a stronger compound / better probe for the same target; or return to in vitro assays to confirm whether the target is truly engaged |
2. Selectivity: minimal non-target interference | At least selectivity information versus same-family and high-risk targets; broader profiling when available | Determines whether the phenotype can be primarily attributed to the target; otherwise it behaves like a multi-target tool | Add family panel / key off-target checks; downgrade claim strength to “suggestive association,” not target attribution |
3. Cellular on-target evidence: true engagement in cells | Target engagement (prefer direct/proximal measures) or reliable surrogate PD markers; state whether the target is accessible in your cells and whether expression/complex state affects accessibility | The Portal FAQ notes: without target engagement, it’s hard to tell whether “inactive/effective” reflects the target or the system, and hard to define a rational dose window | Use more proximal binding/occupancy assays; or use reliable PD markers to establish an “occupancy–phenotype” relationship |
4. Matched negative control: close analog but inactive/weakened on-target | Structurally close (ideally changing only key interaction points) + clearly reduced on-target activity; clarify whether it may still have other off-targets | Excludes non-specific phenotypes driven by scaffold/physicochemical properties | If an ideal negative control is unavailable, at least use a second (orthogonal) scaffold probe (see Item 5) to strengthen causality |
5. Orthogonal probe: different scaffold, same target, same-direction effect | Two structurally distinct probes for the same target producing consistent results within a reasonable dose window | The Portal FAQ recommends using two different chemotypes per target, ideally with inactive analogs; distinct scaffolds are unlikely to share the same off-target profile, so consistent effects are more credible | With only one probe, conclusions must be more restrained; prioritize finding a second chemotype via Portal/SGC, etc. |
6. Exposure–toxicity boundary: “effective” should not mean “damaging cells” | Run viability/toxicity/stress readouts near effective concentrations; follow recommended maximum dose / empirical upper limits | The Portal also cautions: mere growth inhibition/death is usually not specific; the platform often provides recommended cellular dose caps | Use dose gradients to find the “lowest effective, low-toxicity” window; if needed, switch to a cleaner probe or adjust treatment timing |
5.2 Three Key Reminders and How to Handle Them
Three key reminders | Typical appearance (what you’ll observe) | Common causes (why it happens) | Most effective response |
1) Structural alerts / interference compounds: mistaking false positives for hits | The same compound “works” in many unrelated systems; effect disappears when switching assay formats; strong effects without a reasonable dose relationship | PAINS / readout interference, colloidal aggregation, non-specific reactivity, redox cycling, etc. | Run anti-interference checks (aggregation/readout/reactivity); consult Chemical Probes Portal expert reviews and Unsuitables to avoid using compounds unsuitable as probes |
2) Cytotoxicity disguised as pathway effects | “Stronger looks better,” but viability drops and stress increases; or effects only appear at high doses | Broad off-targets and cellular collapse at high dose; phenotype becomes non-attributable | Run viability/toxicity/stress readouts near effective doses; bind conclusions to the low-tox window; if needed, switch probes or shorten exposure |
3) No controls: making causal claims from a single molecule | Only “one probe + vehicle control,” yet concluding “this target causes this phenotype” | Any single compound can have unknown off-targets; evidence is inherently incomplete. Portal FAQ explains why “orthogonal probe + negative control” is recommended, and also notes negative controls are not foolproof | Prioritize adding a second chemotype probe; add matched negative controls when possible; if neither exists, downgrade claims to “suggestive association / needs further validation,” not “attributed” |
6. Product Navigation Table | Small-Molecule Chemical Probes / Chemical Proteomics: How to Choose Between Tables A–D
Need / scenario (typical question) | Start with which table | Why this table is the best fit | What you can find in this table |
Getting started with lysis / sample prep: proteins won’t solubilize, samples are unstable, digestion is inconsistent | Table A | Sample lysis & proteomics sample preparation | If the sample state is not right, downstream click, enrichment, and LC-MS won’t be comparable; background and reproducibility will collapse |
After lysis, you need “reduction → alkylation” and worry about disulfide reshuffling or high thiol background | Table A | Sample lysis & proteomics sample preparation | A foundational step in proteomics/chemical proteomics that directly determines labeling consistency and peptide quality |
Your probe has an alkyne/azide and you need to “click on” biotin/fluorophore (CuAAC) | Table B | Click chemistry (CuAAC) & copper-removal system | CuAAC success is largely dictated by whether the copper source + reductant + ligand + copper quench/removal are properly matched; this table provides the core kit |
Click reaction is incomplete / signal is weak: nothing shows up on gel or LC-MS enrichment | Table B | Click chemistry (CuAAC) & copper-removal system | Common causes cluster around insufficient generation/stabilization of Cu(I), mismatched ligands, or copper being consumed by impurities—checking the catalytic system first is most efficient |
High background, protein oxidation, yellowing samples: suspect copper-mediated side reactions | Table B | Click chemistry (CuAAC) & copper-removal system | You generally need a more biocompatible ligand + thorough copper quenching/removal to suppress copper-related background |
Installing a handle/linker/tag onto a parent scaffold: making probe derivatives or intermediates | Table C | Probe derivatization & coupling activation | The core of probe construction: activation → coupling → handle/linker introduction |
Coupling/acylation in organic phase is slow / low yield and needs catalysis or acid scavenging | Table C | Probe derivatization & coupling activation | Key is whether the coupling reagent + base + catalyst combination is合理/appropriate |
Building covalent probes / reactive fragments: focusing on Cys reactivity, wanting a warhead or to cap background | Table D | Enrichment & “probe-enabling” modules | This table groups covalent labeling + background control + quench/competition controls, which best matches covalent-probe/ABPP workflows |
Need pull-down enrichment: streptavidin/avidin systems, or want mild elution | Table D | Enrichment & “probe-enabling” modules | Enrichment tags and elution strategy determine whether you can pull down efficiently, wash cleanly, and recover well |
Want photoaffinity probes: “freeze” transient binding for identification | Table D | Enrichment & “probe-enabling” modules | Photo-crosslinking is a probe structural module and is often combined with click/enrichment to form a complete evidence chain |
Preparing stock solutions / treating cells / making LC-MS mobile phases: worried about solubility and MS background | Table D | Enrichment & “probe-enabling” modules | Solvents and acidic additives define the usable concentration window and strongly affect MS background/ionization |
Summary:
1. Get sample handling running smoothly → see Table A
2. Probe has a handle and needs CuAAC → see Table B
3. Need to synthesize/derivatize the probe molecule itself → see Table C
4. Need enrichment / covalent labeling / photo-crosslinking / solvents & LC-MS additives → see Table D
Table A | Sample Lysis & Proteomics Sample Preparation (Denaturation / Detergents / Reduction–Alkylation / Buffers / Water)
Category | CAS No. | Aladdin Cat. No. | Name | Spec / Purity | Use & selection notes (small-molecule probes) |
Ultrapure water / system water | 7732-18-5 | Cell-biology-grade water | For cell biology; endotoxin-free, pyrogen-free; ultrafiltered and autoclaved | Use high-purity water for cell/proteomics workflows to reduce background fluctuations from endotoxin and impurities; for preparing click/buffer/wash systems. | |
Proteomics / sample lysis | Denaturant | 57-13-6 | U432962 | Urea | Beads | Common protein denaturant/solubilizer for lysis and unfolding to expose binding sites and improve digestion efficiency; in proteomics prep it is typically diluted to low concentration to avoid inhibiting enzymes and to reduce MS background. |
Proteomics / sample lysis | Strong denaturant | 50-01-1 | Guanidine hydrochloride | For protein analysis, ≥99.5% | Strong denaturant/solubilizer: useful for difficult proteins and complexes; for probe enrichment/proteomics prep it is typically diluted/exchanged to remain compatible with digestion and MS. | |
Proteomics / sample lysis | Detergent | 151-21-3 | Sodium dodecyl sulfate (SDS) | For electrophoresis; anionic | Strong anionic surfactant commonly used to lyse and solubilize membrane proteins/complexes; however it markedly interferes with tryptic digestion and LC-MS, so it usually needs removal before MS (lower background, better reproducibility). | |
Protein sample handling | Reductant (break disulfides) | 3483-12-3 | DL-Dithiothreitol (DTT) | For electrophoresis, ≥99% | High-frequency reagent for disulfide reduction; used in proteomics prep (reduction → alkylation) and before thiol reactions to improve labeling and digestion consistency. | |
Protein sample handling | Reductant (stable) | 51805-45-9 | Tris(2-carboxyethyl)phosphine hydrochloride (TCEP·HCl) | UltraBio™; suitable for electrophoresis; SDS-PAGE tested | Stable aqueous reductant for disulfide reduction, with fewer thiol-related side reactions; commonly used in proteomics reduction steps and as pretreatment before thiol reactions. | |
Protein sample handling | Cys alkylation/capping | 144-48-9 | Iodoacetamide (IAA) | Moligand™, ultrapure, ≥99% (NMR) | Classic proteomics alkylation reagent: caps Cys after reduction to prevent re-oxidation/disulfide reshuffling; also used to evaluate thiol-related background and labeling consistency. | |
Proteomics | Volatile buffer salt | 1066-33-7 | Ammonium bicarbonate | Reagent grade | Volatile buffer salt commonly used for proteomics digestion (LC-MS compatible); used for trypsin digestion and building buffering systems prior to desalting. | |
Thiol chemistry | Reduction/maintenance | 60-24-2 | β-Mercaptoethanol | For cell culture; suitable for electrophoresis; molecular-biology grade, ≥99% | Reducing additive used to maintain thiols in the reduced state and reduce disulfide reshuffling; can also serve as a quencher after covalent probes/thiol reactions to lower background from residual electrophiles. |
Table B | Click Chemistry (CuAAC) & Copper-Removal System (Copper source / reductant / ligand / quench)
Category | CAS No. | Aladdin Cat. No. | Name | Spec / Purity | Use & selection notes (small-molecule probes) |
Click chemistry | Copper source (Cu(II) precursor) | 7758-99-8 | Copper(II) sulfate pentahydrate | For plant cell culture, ≥98% | Common Cu(II) source for CuAAC; paired with sodium ascorbate to generate Cu(I) in situ to catalyze azide–alkyne click coupling—useful for “clicking on” tags to probe handles. | |
Click chemistry | Direct Cu(I) source | 7787-70-4 | Copper(I) bromide | PrimorTrace™, ≥99.99% metals basis | Frequently used Cu(I) salt for CuAAC; with ligands it improves Cu(I) stability and reaction efficiency—useful for condition screening. | |
Click chemistry | Direct Cu(I) source | 7681-65-4 | Copper(I) iodide | Anhydrous, ≥99.995% metals basis | Direct Cu(I) source for CuAAC; often combined with ligands (TBTA/THPTA) to improve stability and click efficiency—useful for screening/optimization. | |
Click chemistry | Reductant (generate Cu(I)) | 134-03-2 | Sodium ascorbate | For cell culture, ≥99% | Standard CuAAC reductant: reduces Cu(II) to Cu(I) to form the active catalyst; used for assembling and optimizing click reaction systems. | |
Click chemistry | CuAAC ligand (biocompatible) | 760952-88-3 | Tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) | ≥97% | Common aqueous CuAAC ligand: improves click efficiency and reduces copper-mediated oxidative damage; widely used in lysate/protein sample click and chemical proteomics workflows. | |
Click chemistry | CuAAC ligand (classic) | 510758-28-8 | Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) | ≥95% | Classic CuAAC ligand: stabilizes Cu(I) and improves selectivity; often used for condition screening (in aqueous systems it typically requires co-solvents or solubility optimization). | |
Metal chelation / termination | Metal removal / background control | 6381-92-6 | Disodium EDTA dihydrate | For plant cell culture, ≥99% | Chelates metal ions to suppress metal-catalyzed side reactions and protect samples; after CuAAC it can be used to terminate/de-copper and reduce copper-related oxidation and background. | |
Click termination / de-copper | Selective Cu(I) chelator | 52698-84-7 | Bathocuproine disulfonate disodium salt | ≥97% | BCS: highly selective for Cu(I); used for rapid post-click quenching and copper removal to reduce copper-related oxidation and nonspecific background. |
Table C | Probe Derivatization & Coupling Activation (EDC/NHS/DCC + base/catalyst + handle / alternative linkage)
Category | CAS No. | Aladdin Cat. No. | Name | Spec / Purity | Use & selection notes (small-molecule probes) |
Coupling activation | Water-soluble carbodiimide | 25952-53-8 | Aladdin™ EDC | Analytical standard | Core reagent for carboxyl–amine coupling; frequently used to attach handles/linkers/tags to parent molecules or carriers (more aqueous-leaning systems), a high-frequency tool for probe derivatization. | |
Coupling activation | NHS additive (active-ester formation) | 6066-82-6 | N-Hydroxysuccinimide (NHS) | ≥98% | Used with EDC/DCC to form NHS active esters and boost carboxyl–amine coupling efficiency; used to build probe intermediates that can further accept handles/tags. | |
Coupling activation | Organic-phase carbodiimide | 538-75-0 | N,N′-Dicyclohexylcarbodiimide solution (DCC) | 1.0 M in methylene chloride | Common organic-phase coupling reagent for amide/ester formation and linker construction; suitable for the organic synthesis stage of probe derivatization (often higher efficiency with NHS/DMAP/base). | |
Coupling activation | Base (for coupling) | 7087-68-5 | N-Ethyl diisopropylamine solution (DIPEA) | For peptide synthesis, ~2 M in 1-methyl-2-pyrrolidinone | Common organic base for scavenging acid and driving coupling in EDC/NHS or DCC systems; useful in linker/tag derivatization and peptide/probe synthesis steps. | |
Coupling activation | Acylation catalyst | 1122-58-3 | 4-Dimethylaminopyridine (DMAP) | ≥99% | Common catalyst for acylation/esterification; improves DCC/active-ester coupling efficiency; widely used in linker/tag/probe derivative synthesis. | |
Probe handle | Alkyne building block | 2450-71-7 | Propargylamine | ≥98% | Most commonly used alkyne handle building block; introduces an alkyne into the parent scaffold (enabling downstream CuAAC/SPAAC attachment of biotin/fluorophores). | |
Bioorthogonal | Staudinger phosphine reagent | 603-35-0 | Triphenylphosphine | ≥99% (GC) | Classic phosphine reagent: used for azide-related Staudinger reduction/ligation logic (an alternative/orthogonal route or control chemistry beyond click), and also widely used in organic reductions. |
Table D | Enrichment & “Probe-Enabling” Modules (Biotin system + covalent/thiol chemistry + photo-crosslinking + common solvents / LC-MS additives)
Category | CAS No. | Aladdin Cat. No. | Name | Spec / Purity | Use & selection notes (small-molecule probes) |
Enrichment tag | Biotin core | 58-85-5 | Biotin | PharmPure™, USP | Core affinity enrichment tag for streptavidin/avidin pull-down and enrichment; also used for competitive elution and system validation. | |
Enrichment tag | Amine-reactive biotinylation | 35013-72-0 | Aladdin™ NHS-Biotin | ≥99% | Biotin-NHS ester: rapidly couples to amines (Lys/N-terminus) for biotinylation; used to build biotinylated probes/linkers or to prepare biotinylated control samples to validate pull-down workflows. | |
Enrichment tag | Reversible enrichment / mild elution | 533-48-2 | D-Desthiobiotin | ≥95% | Desthiobiotin binds streptavidin but is more readily displaced by biotin, enabling easier/milder competitive elution; suitable when gentle recovery and reduced irreversible adsorption are needed. | |
Thiol site coupling | Maleimide group | 541-59-3 | Maleimide | ≥98% | Preferentially reacts with Cys-SH: used to construct “maleimide-tag/linker/probe” for thiol-site coupling; common in site-specific labeling and conjugation strategies. | |
Thiol chemistry | Capping / background control | 128-53-0 | N-Ethylmaleimide (NEM) | Moligand™, ultrapure, ≥99% | Rapidly caps free thiols (Cys-SH); often used post-lysis to cap/control background, reducing interference from nonspecific thiol reactions and disulfide exchange in probe readouts. | |
Covalent chemistry | Cys-electrophile warhead | 79-07-2 | Chloroacetamide | ≥99% | Strong electrophile for Cys-SH: used in covalent probe/reactive fragment design and as a control; dose and reaction time should be controlled to reduce broad nonspecific labeling. | |
Covalent chemistry | Michael acceptor core / control | 79-06-1 | A108470 | Acrylamide | Moligand™, for electrophoresis, ≥99% | Structural core/control for Michael-acceptor warheads (also used in electrophoresis); practical covalent probes are typically “scaffold–acrylamide” and require tuning reactivity/selectivity to avoid broad nonspecific labeling. |
Nucleophile / quencher | Thiol (control/competition) | 52-90-4 | L-Cysteine | UltraBio™, ≥98.5% (RT) | Thiol nucleophile: used as a quencher/competitor control for covalent probes/electrophiles to distinguish specific labeling from nonspecific reactivity background. | |
Nucleophile / quencher | Antioxidant / thiol precursor | 616-91-1 | N-Acetyl-L-cysteine (NAC) | PharmPure™, USP, Ph.Eur, ≥98.5% | Widely used antioxidant and thiol-related control reagent: helps reduce oxidative-stress background and can serve as a quencher/control for reactive electrophiles (often used in covalent probe workflows and boundary-condition checks in sample handling). | |
Nucleophile / quencher | Intracellular reducing-system control | 70-18-8 | Glutathione (reduced, GSH) | Moligand™, for cell culture, ≥98% | Major intracellular reductant: used to assess stability/“quenching risk” of covalent probes/electrophiles under reducing conditions; also used in competition/quenching experiments to lower nonspecific reactivity background. | |
Photoaffinity module | Benzophenone core | 119-61-9 | Benzophenone | For synthesis | Classic photoaffinity module core; used to build photo-crosslinking probes (UV-triggered covalent capture) to convert transient interactions into identifiable signals. | |
Photoaffinity module | Benzophenone derivative | 134-85-0 | 4-Chlorobenzophenone | ≥99% | Benzophenone photo-crosslinking derivative; used to synthesize photo-crosslinkable probe scaffolds (UV-triggered covalent capture), facilitating downstream enrichment/identification. | |
Photoaffinity module | Benzophenone derivative | 611-94-9 | 4-Methoxybenzophenone | ≥98% (GC) | Benzophenone photo-crosslinking derivative; used to build photoaffinity probes and enable UV covalent capture, supporting interaction identification and target attribution. | |
Solvent | Stock solution / cell treatment | 67-68-5 | Dimethyl sulfoxide (DMSO) | Pharmaceutical grade, PharmPure™ | Most common solvent for probe/small-molecule stocks; convenient for dose-response and cell treatment (typically control the final % to reduce cellular stress/false positives). | |
Solvent | Synthesis/coupling (polar aprotic) | 68-12-2 | N,N-Dimethylformamide (DMF) | Anhydrous, ≥99.8% | Common coupling/derivatization solvent for installing linkers/handles in organic synthesis; also used to prepare some poorly soluble probe intermediates. | |
Solvent | Proteomics precipitation/wash | 67-56-1 | M433281 | Methanol | Preparative chromatography grade | Common for protein precipitation/washing, desalting/defatting, and LC-MS systems; helps lower impurity background and improve run stability. |
Solvent | LC-MS routine solvent | 75-05-8 | Acetonitrile (ACN) | For DNA synthesis, H₂O ≤10 ppm | High-frequency solvent in LC-MS/proteomics: for mobile phases, elution, and sample handling; low water/low impurities helps reduce background and improve reproducibility. | |
LC-MS additive | Acid (sample/mobile phase) | 64-18-6 | F433212 | Formic acid (FA) | Pharmaceutical grade, PharmPure™, ≥98% | Most common acidifier in proteomics/LC-MS (e.g., 0.1%); improves peak shape and is ESI-compatible, suitable for LC-MS runs and desalting workflows. |
LC-MS additive | Acid (sample/mobile phase) | 76-05-1 | Trifluoroacetic acid solution (TFA) | For protein sequencing, 25% solution in water | Often used for peptide dissolution, RP conditions, and some separations; for MS note that TFA can suppress ESI ionization—typically keep it low in LC-MS methods or switch to FA-based systems. |
Note: The above are representative Aladdin products. For more specifications, please refer to the full product list at the end of the article or search the Aladdin website by product name/CAS number.